Loading…
Based on limited metadata without access to the full warning letter text, this FDA warning issued to Chronic Lyme Treatments in May 2020 concerns drug products and their manufacturing or marketing practices. The specific violations cannot be detailed due to the unavailable subject line and letter contents, though the warning indicates the company failed to comply with FDA drug regulations. This warning falls under the FDA's drug enforcement authority and suggests the agency identified deficiencies significant enough to warrant formal regulatory action.